Pharma’s AlphaGo Moment: For the First Time, Artificial Intelligence Has Designed a New Drug in 21 Days
Insilico Medicine succeeds in using AI to design a new molecule from scratch in just 21 days, and validate it in just 25 days, compared to 2-3 years required currently for pharma industry.
This is Pharma’s AlphaGo moment.
In 2015 DeepMind succeeded in developing the first AI capable of beating a human Go champion in Go. This may be an analogous game-changing moment for Pharma. The potential for AI to radically transform Pharma is obvious.
AI System Has Designed, Synthesized and Surpassed Independent Validation of a New Drug in Just 21 Days
September 3, 2019, London, UK: Deep Knowledge Analytics acknowledges the new ground-breaking achievement of Insilico Medicine, which succeeded to design, synthesize and validate a novel drug candidate end-to-end in just 46 days, which is 15 times faster compared to what it typically takes even for the top pharma corporations capable to conduct the most efficient R&D process, as described in a new scientific paper published in the peer-reviewed journal Nature Biotechnology. There is a high probability that this achievement will become a true game-changer for the entire pharmaceutical industry.
PharmTech quoted AI-Friendly CEOs and Board Members report
Deep Knowledge Analytics also released a report examining AI, which examined practices at 50 pharmaceutical companies to identify leaders who are most actively driving the use of AI in their organizations.
The goal of this research is to benchmark the impact of management support on the use of AI and overall efforts to increase R & D efficiency, according to Margaretta Colangelo, managing partner at Deep Knowledge Ventures. She expects future research to find a correlation between level of commitment to AI and market capitalization growth.
Elsevier quoted DKA article on the Pharma R&D Today blog
“China’s ability to generate massive amounts of real-time medical data from more than 1 billion people in the local population, stimulated by rather flexible privacy laws is driving advancement,” writes Margaretta Colangelo of Deep Knowledge Ventures. Though she says that government programs are also helping to grow local AI and data science talent, Colangelo also warns that China is currently lagging behind its competitors in pharma and biotech innovation, which could limit its progress.
Members of the MIT engineering faculty receive many awards in recognition of their scholarship, service, and overall excellence. Every quarter, the School of Engineering publicly recognizes their achievements by highlighting the honors, prizes, and medals won by faculty working in our academic departments, labs, and centers.
Regina Barzilay, Manolis Kellis, Tommi Jaakola and Peter Szolovits were named among “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare” by Deep Knowledge Analytics on Feb. 1.
MIT acknowledged AI ranking made by Deep Knowledge Analytics.
This week four CSAIL faculty were named among the top 100 global leaders in artificial intelligence for health, according to a new report developed by a top technology think-tank.
Deep Knowledge Analytics’s “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare” (PDF) looked at scientists, clinicians and technologists across academia, pharma, and AI companies. Among the honorees were CSAIL principal investigators and MIT professors Regina Barzilay, Tommi Jaakkola, Manolis Kellis and Peter Szolovits.
Deep Knowledge Analytics picked the 'Top 100 AI Leaders in Drug Discovery and Advanced Healthcare’ out of an initial pool of 500 outstanding candidates. Unless a new AI winter wind blows and sweeps over the science explorers, their work is quite likely to enhance the quality of life surpassing the most vivid science fiction imagination.
An Insight Of AI's Penetration In Drug Development Market
A recent article about AI-based drug development, indicates the progressive use of A.I. technologies for the drug production industry, mining the huge amount of data collected from the pharmaceutical companies’ data centers. Thanks to Deep Knowledge Ventures which a couple of days ago updated their research data, we took the opportunity to delve into the latest developments of this market.
Billions are being bet to find the next revolutionary drug. In 2013, US start-up Berg was asked by the Department of Defense to help improve the detection of prostate cancer, a disease common among pilots. Less than five years later, an artificial intelligence-driven tool has been tested on more than 1,000 patients with promising results.
A major report by Big Innovation Centre and Deep Knowledge Analytics places the UK in the third spot in the global rankings for Artificial Intelligence (AI) and it foresees it excelling in specific subsectors and areas in the coming years.
"Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials. Moreover, 75% of newly approved drugs are unable to cover the cost of development and some analysts predict that ROI in pharmaceutical R&D may hit zero by 2020."
Deep Knowledge Analytics, the analytical arm of Deep Knowledge Ventures, in coordination with Future FinTech announces the release of a special report on the topic of financial inclusion: “FinTech for Social Good”.
Monday, July 16, London: Big Innovation Centre, DAG Global and Deep Knowledge Analytics announce the release of a first-of-its-kind, 960-page report on the state of the Blockchain Industry in the United Kingdom.
Deep Knowledge Analytics, together with Future FinTech, produced a new updated edition of our previous “Developing World Financial Inclusion” analytical report. This new 450-page document, timed to Quarter 2 of 2018, provides a much deeper overview of industry